Marksans Pharma Limited (MARKSANS) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Marksans Pharma Limited ₹358, price ₹326, upside +10.0%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Marksans Pharma Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ₹38.82 – ₹352.16 · fair‑value band ₹212.29 – ₹482.02 · the ₹325.60 price screens below the ₹358.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 2, 2026.
Follow Marksans Pharma in your weekly email
Every Wednesday you see whether Marksans Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally.
Show more
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Stock analysis
Marksans Pharma Limited (MARKSANS) currently trades at ₹325.60, while our model-based Fair Value estimate is ₹358.16, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹219.65 per share, and 1 of the 26 models we run sit above the ₹325.60 price.
Bear case: the Asset-Based group reads lowest at ₹44.70, and 25 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹212.29 (bear) to ₹482.02 (bull), the price of ₹325.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Marksans Pharma Limited reported revenue of ₹29.5B in FY2026 versus ₹14.8B in FY2022, a compound +18.8%/yr. Reported net income was ₹4.2B in FY2026, compounding +22.7%/yr from FY2022.
Key figures
Market cap ₹148B (≈ $1.5B) · P/E ratio 28.5 · P/S ratio 4.04 · EPS (TTM) ₹11.41 · Dividend yield 0.3% · Net margin 14.2% · Return on equity 15.2% · Return on assets (EBIT) 21.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (medium confidence).
What moves the price
The share trades about 6% below its 52-week high and 108% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 10%, MARKSANS screens cheaper than that median.
Fair Value models
Bear ₹212.29Fair Value ₹358.16Bull ₹482.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹5.36 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Start year 2021 (pandemic). Over 10 years: +12.7% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+15.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.4%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.15.4% vs 17.0%, steady
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 17%
Start year 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+34.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +28.9% a year for the price and +8.9% for the forecasts.
Compare Marksans Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Below median
Fair Value upside+10.0% · Above median
Profitability
Return on equity (TTM)15.2% · Above median
Return on assets8.9% · Above median
Net margin (TTM)16.3% · Above median
Operating margin (TTM)22.4% · Above median
Growth and dividend
Revenue growth35.6% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Marksans Pharma Limited (MARKSANS) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹358.16 versus a price of ₹325.60, about +10% upside (undervalued).
What is the fair value of MARKSANS?
Our model-based fair value for Marksans Pharma Limited is ₹358.16 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹325.60.
What is the quality score of MARKSANS?
Marksans Pharma Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Marksans Pharma Limited (MARKSANS)?
Our model-based price target is the fair value of ₹358.16 (as of Oct 2, 2026) from 26 valuation models. Cautious scenario ₹212.29, optimistic scenario ₹482.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Marksans Pharma Limited stock forecast for 2026?
Our models put fair value at ₹358.16, about +10% upside versus a price of ₹325.60 (undervalued). Cautious scenario ₹212.29, optimistic scenario ₹482.02. The calculation is refreshed regularly with new filings.
What is the revenue of Marksans Pharma Limited (MARKSANS)?
Marksans Pharma Limited reported trailing-twelve-month revenue of about ₹31.7B (latest available figure, as of Oct 2, 2026).
Does Marksans Pharma Limited pay a dividend?
Marksans Pharma Limited currently shows a dividend yield of about 0.28% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Marksans Pharma Limited (MARKSANS)?
For today's price to be fair in a discounted-cash-flow model, Marksans Pharma Limited would have to grow free cash flow by +34.2 % per year for five years (discount rate 14.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.6 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of MARKSANS use?
Our models discount Marksans Pharma Limited at 14.4 %: a base by market capitalisation (small), damped by beta 1.15, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Marksans Pharma Limited that is +34.2 % per year a year over ten years, using the same discount rate (14.4 %) and the same formula as our fair value.
How much growth has Marksans Pharma Limited (MARKSANS) delivered so far?
Over the past 5 years revenue at Marksans Pharma Limited grew +16.6 % a year. The price currently implies +34.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Marksans Pharma Limited (MARKSANS) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Marksans Pharma Limited (+34.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Marksans Pharma Limited (MARKSANS)?
The free-cash-flow yield on the price is 2.38 %: that much free cash flow Marksans Pharma Limited produces per unit of market value. When it exceeds the discount rate of our models (14.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Marksans Pharma Limited (MARKSANS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Marksans Pharma Limited it is ₹358.16 per share (as of Oct 2, 2026), against a price of ₹325.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Marksans Pharma Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, MARKSANS trades below its calculated fair value: price ₹325.60, fair value ₹358.16, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MARKSANS?
No. The price is what the market pays today (₹325.60); the fair value is what the company's own numbers justify (₹358.16). For Marksans Pharma Limited the two are ₹32.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is Marksans Pharma Limited worth?
The market values Marksans Pharma Limited at about ₹148B (market capitalisation, as of Oct 2, 2026). Per share that is ₹325.60; our models calculate a fair value of ₹358.16 per share.
What do the bullish and bearish scenarios say about MARKSANS?
Our models span a range for Marksans Pharma Limited: cautious scenario ₹212.29, base ₹358.16, optimistic ₹482.02 per share (as of Oct 2, 2026, price ₹325.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MARKSANS?
Marksans Pharma Limited trades at a price-to-earnings ratio of 28.5 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹358.16 is built from several models across several years. Other multiples: PEG 1.1, P/B 4.9, P/S 4.7, EV/EBITDA 20.3.
What is the PEG ratio of MARKSANS?
The PEG ratio of Marksans Pharma Limited is 1.12 (P/E divided by earnings growth, as of Oct 2, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Marksans Pharma Limited (MARKSANS)?
Balance-sheet figures for Marksans Pharma Limited (as of Oct 2, 2026): return on equity 15.2%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is MARKSANS from its 52-week high?
Marksans Pharma Limited trades at ₹325.60, about 6% below its 52-week high of ₹347.60 and 108% above the low of ₹156.89 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹358.16 is for.
Which stocks are comparable to Marksans Pharma Limited?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Marksans Pharma Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹325.60, calculated fair value ₹358.16 (+10%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MARKSANS calculated?
We run Marksans Pharma Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹358.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Marksans Pharma Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Marksans Pharma Limited (MARKSANS)?
The closing price on Oct 1, 2026 was ₹325.60. Our model-based fair value is ₹358.16, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Marksans Pharma Limited right now?
A fairly wide model range (₹212.29 to ₹482.02) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Marksans Pharma Limited (MARKSANS) come from?
Earnings per share at Marksans Pharma Limited grew +19.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +12.3 %, EBIT margin +9.7 %, tax rate +0.2 %, residual (interest, one-offs) −3.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Marksans Pharma Limited
How large is the market capitalisation of Marksans Pharma Limited (MARKSANS)?
The market capitalisation of Marksans Pharma Limited is ₹148B (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Marksans Pharma Limited (MARKSANS)?
The price-to-sales ratio of Marksans Pharma Limited is 4.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Marksans Pharma Limited (MARKSANS)?
Earnings per share at Marksans Pharma Limited are ₹11.41 (price ÷ EPS = P/E 28.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Marksans Pharma Limited (MARKSANS)?
The dividend yield of Marksans Pharma Limited is 0.3% (payout 7.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Marksans Pharma Limited (MARKSANS)?
The net margin of Marksans Pharma Limited is 14.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Marksans Pharma Limited (MARKSANS)?
The return on equity (ROE) of Marksans Pharma Limited is 15.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Marksans Pharma Limited (MARKSANS)?
On an EBIT basis the return on assets of Marksans Pharma Limited is 21.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Marksans Pharma Limited (MARKSANS)?
The operating margin of Marksans Pharma Limited is 22.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Marksans Pharma Limited (MARKSANS)?
Revenue at Marksans Pharma Limited is growing +35.6% versus a year earlier (3y avg +16.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Marksans Pharma Limited (MARKSANS)?
Earnings per share at Marksans Pharma Limited are growing +169% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Marksans Pharma Limited (MARKSANS) hold?
Marksans Pharma Limited holds more cash than debt, ₹6.5B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Marksans Pharma Limited in the live analysis
One click puts Marksans Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
